

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification <sup>6</sup>:</b> <b>A61K 31/315 // (A61K 31/315, 31:20)</b>	<b>A1</b>	<b>(11) International Publication Number:</b> <b>WO 95/13806</b> <b>(43) International Publication Date:</b> 26 May 1995 (26.05.95)
<b>(21) International Application Number:</b> PCT/GB94/02370 <b>(22) International Filing Date:</b> 28 October 1994 (28.10.94) <b>(30) Priority Data:</b> 9323808.7 18 November 1993 (18.11.93) GB <b>(71) Applicant (for all designated States except US):</b> KAPPA PHARMACEUTICALS LIMITED [GB/GB]; Alexander House, Gatehampton Road, Goring-on-Thames, Reading, Berkshire RG8 0EN (GB). <b>(72) Inventor; and</b> <b>(75) Inventor/Applicant (for US only):</b> BRYCE-SMITH, Derek [GB/GB]; Highland Wood House, Mill Lane, Kidmore End, Reading, Berkshire RG4 9HB (GB). <b>(74) Agents:</b> McNEIGHT, David, Leslie et al.; McNeight & Lawrence, Regent House, Heaton Lane, Stockport, Cheshire SK4 1BS (GB).		<b>(81) Designated States:</b> JP, US, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).  <b>Published</b> <i>With international search report.</i>
<b>(54) Title:</b> COMPOSITIONS CONTAINING ZINC LINOLEATE FOR THE TREATMENT OF SKIN DISORDERS  <b>(57) Abstract</b>  There is disclosed a composition for the treatment of skin disorders comprising zinc linoleate and free linoleic acid in a pharmaceutically acceptable carrier.		

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	GB	United Kingdom	MR	Mauritania
AU	Australia	GE	Georgia	MW	Malawi
BB	Barbados	GN	Guinea	NE	Niger
BE	Belgium	GR	Greece	NL	Netherlands
BF	Burkina Faso	HU	Hungary	NO	Norway
BG	Bulgaria	IE	Ireland	NZ	New Zealand
BJ	Benin	IT	Italy	PL	Poland
BR	Brazil	JP	Japan	PT	Portugal
BY	Belarus	KE	Kenya	RO	Romania
CA	Canada	KG	Kyrgyzstan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SI	Slovenia
CI	Côte d'Ivoire	LI	Liechtenstein	SK	Slovakia
CM	Cameroon	LK	Sri Lanka	SN	Senegal
CN	China	LU	Luxembourg	TD	Chad
CS	Czechoslovakia	LV	Latvia	TG	Togo
CZ	Czech Republic	MC	Monaco	TJ	Tajikistan
DE	Germany	MD	Republic of Moldova	TT	Trinidad and Tobago
DK	Denmark	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	US	United States of America
FI	Finland	MN	Mongolia	UZ	Uzbekistan
FR	France			VN	Viet Nam
GA	Gabon				

-1-

COMPOSITIONS CONTAINING ZINC LINOLEATE  
FOR THE TREATMENT OF SKIN DISORDERS

This invention concerns a composition containing zinc for the treatment of skin disorders.

Conventional zinc containing creams and ointments comprise zinc in the form of zinc oxide.

Zinc oxide is a form of zinc highly insoluble in water, lipids and non-polar solvents and is thus merely suspended in a pharmaceutical carrier to produce a white ointment or cream which is poorly absorbed into the skin leaving unsightly deposits on the skin after use.

The present invention overcomes, at least to some extent, the problems aforesaid.

According to the present invention there is provided a composition for the treatment of skin disorders comprising zinc linoleate and free linoleic acid in a pharmaceutically acceptable carrier.

Zinc linoleate is a colourless and fat soluble form of zinc which is readily absorbed into the skin.

-2-

Since it is known that slightly acidic compositions are better absorbed by the skin than neutral or alkaline preparations, free linoleic acid is included in the composition to adjust the pH of the composition to around pH 5.5.

The composition may comprise a zinc ion content of 0.1 to 8.5%, and preferably between 1 and 5%.

The composition may comprise a free linoleic acid content of 0.1 to 50%.

The composition may also comprise zinc oleate, zinc oxide, zinc salts of conjugated isomers of linoleic acid, water and an emulsifying agent.

The composition may also comprise an antioxidant, for example, vitamin E or vitamin A.

The composition may also comprise vitamin D<sub>3</sub> or any other additive known to have properties beneficial to any skin condition.

The composition may be used topically to relieve the symptoms of a variety of skin conditions, for example, eczema, dermatitis, psoriasis, acne vulgaris, nappy rash.

-3-

The composition may also comprise an antibacterial constituent, for example, zinc iodate, potassium iodate, an iodophor or cetylpyrididum chloride. Such a composition is envisaged to be of particular use for the treatment of minor cuts and abrasions as well as more severe leg and other cutaneous ulcers.

The composition may also comprise a minor proportion of copper ions, preferably in the form of copper linoleate.

The composition may also comprise a local anaesthetic, for example, lignocaine. Such a preparation would give rapid symptomatic relief of itching and/or pain.

The pharmaceutically acceptable carrier may comprise emulsifying ointment BP or any other suitable carrier, for example, soft/hard paraffin.

The composition may be applied topically to the skin in the form of a cream or ointment, or via a pad or bandage pre-soaked in the composition, or by any other mode of administration capable of delivering an effective amount of composition to the site of injury.

-4-

The composition may vary in consistency from a cream to an ointment by varying its water content.

It is envisaged that a zinc linoleate cream according to the present invention may be used in cosmetics and sunscreen lotions.

According to a second aspect of the invention there is provided a method of manufacture of a composition for the treatment of skin disorders comprising zinc linoleate and free linoleic acid in a pharmaceutically acceptable carrier.

A method of manufacture may comprise mixing zinc oxide in a suitable carrier, for example, emulsifying ointment BP, adding linoleic acid and heating with stirring to a temperature sufficient to convert essentially all the zinc oxide into zinc linoleate whilst leaving sufficient free linoleic acid to maintain a slightly acidic pH of the composition upon cooling.

An example of this method of manufacture of the composition of the present invention comprises stirring together 15g zinc oxide with 250g emulsifying ointment BP and warming until fluid. 227ml of linoleic acid is then stirred into the mixture which is heated to 70°C until the liquid turns pale yellow and is only slightly

-5-

turbid. The mixture is then left to cool with stirring to give the composition of the present invention.

The linoleic acid used may not be pure linoleic acid but may comprise 68% linoleic acid, 22% oleic acid and 10% conjugated isomers of linoleic acid, (as manufactured by Hercules, USA).

Part of the linoleic acid may be in the form of a glyceride.

The amount of free linoleic acid present in the composition may be varied by varying the amount of zinc oxide present.

Water may be added to the composition before cooling to vary the consistency of the composition. This step requires vigorous stirring in order to emulsify the mixture, for example, 100ml of water was added to the mixture disclosed above, whilst warm, with vigorous agitation prior to cooling to give a softer product.

Alternatively, the composition may be manufactured by the method of dispersing pre-formed zinc linoleate and free linoleic acid in a suitable carrier.

-6-

A small scale test on 5 individuals suffering from dermatitis showed that application of the composition of the present invention rapidly relieved all symptoms thereof. Itching ceased within ten minutes. In another test, the ointment of the present invention was used with four individuals suffering from psoriasis. All showed considerable benefit within two weeks.



**CLAIMS**

1. A composition for the treatment of skin disorders comprising zinc linoleate and free linoleic acid in a pharmaceutically acceptable carrier.
2. A composition according to claim 1 having a pH of around 5.5
3. A composition according to claim 1 or claim 2 having a zinc ion content of 0.1 to 8.5%.
4. A composition according to any preceding claim having a free linoleic acid content of 0.1 to 50%.
5. A composition according to any preceding claim further comprising one or more of zinc oleate, zinc oxide, zinc salts of conjugated isomers of linoleic acid, an antioxidant (for example vitamin E or vitamin A), vitamin D<sub>3</sub>, an antibacterial constituent (for example, zinc iodate, potassium iodate, an iodophor or cetylpyridinium chloride), a minor proportion of copper ions (preferably in the form of copper linoleate) and a local anaesthetic (for example, lignocaine).
6. A composition according to any preceding claim wherein the pharmaceutically acceptable carrier comprises an emulsifying ointment.
7. A composition according to claim 6 wherein the carrier includes water.

- 8 -

8. A composition according to any preceding claim included in a cosmetic or sunscreen lotion.

9. A method of manufacture of a composition for the treatment of skin disorders comprising zinc linoleate and free linoleic acid in a pharmaceutically acceptable carrier comprising the steps of mixing zinc oxide in a suitable carrier, adding linoleic acid and heating with stirring to a temperature sufficient to convert essentially all the zinc oxide into zinc linoleate whilst leaving sufficient free linoleic acid to maintain a slightly acid pH of the composition upon cooling.

10. A method of manufacture of a composition for the treatment of skin disorders comprising zinc linoleate and free linoleic acid in a pharmaceutically acceptable carrier comprising dispersing pre-formed zinc linoleate and free linoleic acid in said carrier.

# INTERNATIONAL SEARCH REPORT

Internat. U. Appl. No.  
PCT/GB 95/02370

A. CLASSIFICATION OF SUBJECT MATTER  
IPC 6 A61K31/315 //(A61K31/315,31:20)

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)  
IPC 6 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	GB,A,2 217 602 (MEDVET SCIENCE PTY LTD) 1 November 1989 see abstract see page 3, line 3 - line 6 -----	1-10

☐ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

### \* Special categories of cited documents :

- \*A\* document defining the general state of the art which is not considered to be of particular relevance
- \*E\* earlier document but published on or after the international filing date
- \*L\* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- \*O\* document referring to an oral disclosure, use, exhibition or other means
- \*P\* document published prior to the international filing date but later than the priority date claimed

\*T\* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

\*X\* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

\*Y\* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

\*&\* document member of the same patent family

Date of the actual completion of the international search

20 February 1995

Date of mailing of the international search report

24.02.95

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax (+31-70) 340-3016

Authorized officer

Leherte, C

### Impact on patent family members

PCT/GB 02370

Form PCT/ISA/218 (patent family annex) (July 1992)